CRIS
Curis Inc
stockNASDAQ
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis's pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.83 | 2026-09-28 | -2.92% | -4.030 |
| 1M | 1.35 | 2026-09-04 | -40.22% | -0.256 |
| 3M | 5.94 | 2026-07-06 | -86.41% | 1.184 |
| 6M | 0.53 | 2026-04-06 | +51.43% | 17.852 |
| 1Y | 1.66 | 2025-10-06 | -51.38% | 9.703 |
| 2Y | 5.08 | 2024-10-04 | -84.11% | — |
| 5Y | 161.80 | 2021-10-05 | -99.50% | 1.970 |
Curis Inc (NASDAQ:CRIS) stock price today is $0.81, and today's volume is 100,347. CRIS is down 2.841% today. The 30 day average volume is 145,608. CRIS market cap is $1.96M with 2.43M shares outstanding.